Crystal structure of BCL-2 F104L mutation with venetoclax

Structure

x-ray diffraction · 1 distinct chain · 77% helix, 0% strand (DSSP).

Ligands and binding sites

• LBM · 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide · ligand · chains A
• PEG · Di(hydroxyethyl)ether · additive · 4 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

Compared structures

• 6O0M · crystal structure of BCL-2 F104L mutation with venetoclax · the same entry in another collection · chain A against A, TM-score 1.00
• P10415 · AlphaFold monomer V2.0 prediction for apoptosis regulator BCL-2 (P10415) · a predicted model of the same protein · chain A against A, TM-score 0.96
• Q07817 · AlphaFold monomer V2.0 prediction for BCL-2-like protein 1 (Q07817) · a predicted model of the same protein · chain A against A, TM-score 0.94

Analyse

• Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
• Every structure of UniProt P10415
• Every structure of UniProt Q07817
• Elsewhere: RCSB PDB 6O0M · PDBe 6O0M · UniProt P10415 · UniProt Q07817